Factors implicated in radiation therapy failure and radiosensitization of prostate cancer.
Factors implicated in radiation therapy failure and radiosensitization of prostate cancer.
复制标题
DOI：
10.1155/2012/593241
复制
发表时间：
2012
期刊：
影响因子：
4.2
通讯作者：
Bonkhoff H
中科院分区：
文献类型：
--
作者：
Bonkhoff H
组织标志物可能有助于提高前列腺癌（PCa）放射治疗（RT）失败的预测。在放射治疗肿瘤学小组进行的III期随机试验中检测的各种生物标志物中，p16、Ki-67、MDM 2、考克斯-2和PKA在预测RT失败方面产生了最可靠的数据。RT失败中涉及的其他途径也与去势抵抗性PCa的发展有关，包括超敏雄激素受体、EGFR、VEGF-R和PI 3 K/Akt。它们中的大多数甚至在最初诊断时在PCa组织中也是可检测的。新出现的证据表明，RT失败的PCa的结果从一个多因素和异质性的疾病过程。许多组织标志物可用于识别RT失败的高风险患者。其中一些标志物有望被目前可用的药物靶向，以提高RT的疗效并延缓疾病进展。
Tissue markers may be helpful in enhancing prediction of radiation therapy (RT) failure of prostate cancer (PCa). Among the various biomarkers tested in Phase III randomized trials conducted by the Radiation Therapy Oncology Group, p16, Ki-67, MDM2, COX-2, and PKA yielded the most robust data in predicting RT failure. Other pathways involved in RT failure are also implicated in the development of castration-resistant PCa, including the hypersensitive androgen receptor, EGFR, VEGF-R, and PI3K/Akt. Most of them are detectable in PCa tissue even at the time of initial diagnosis. Emerging evidence suggests that RT failure of PCa results from a multifactorial and heterogeneous disease process. A number of tissue markers are available to identify patients at high risk to fail RT. Some of these markers have the promise to be targeted by drugs currently available to enhance the efficacy of RT and delay disease progression.